A trial comparing a combination of surgery and sunitinib with sunitinib alone for kidney cancer that has spread (CARMENA)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Kidney cancer
Renal cell carcinoma




Phase 3

This trial is looking at whether or not surgery helps people who are having sunitinib for kidney cancer that has spread to other parts of the body.

The most common type of kidney cancer is renal cell cancer. There are several different types of renal cell cancer that are identified by looking at the cancer cells under a microscope. The most common is clear cell.

Treatment for renal cell cancer has improved during the last few years with the development of new biological therapies.

Sunitinib is a type of biological therapy called a tyrosine kinase inhibitor (TKI for short). TKIs block tyrosine kinase, which is a chemical messenger that sends messages telling cells to divide and grow. Blocking the effect of tyrosine kinase may stop cancer cells growing.

If the cancer has spread outside your kidney, having an operation to remove your kidney (a nephrectomy) will not cure the disease, and it is a big operation to have. In the past, having surgery to remove the kidney did help people to live longer. But with the new types of biological therapy now available, doctors don’t know if people still benefit from having this type of surgery.

The aim of this trial is to find out if having surgery to remove the kidney as well as sunitinib is better at treating clear cell renal cancer than sunitinib alone.

Who can enter

You can enter this trial if you

  • Have clear cell kidney cancer that has spread to other parts of your body
  • Are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
  • Are able to have surgery to remove your kidney (nephrectomy)
  • Are going to have sunitinib to treat your kidney cancer
  • Have satisfactory blood test results
  • Are willing to use reliable contraception if there is any chance you or your partner could become pregnant
  • Are at least 18 years old

You cannot enter this trial if you

  • Have already had treatment for kidney cancer
  • Have cancer in both kidneys
  • Have cancer that has spread to your brain unless it has been successfully treated in the last 6 weeks, is not causing symptoms and you don't need to take steroids
  • Have a serious heart problem or any other serious medical problems
  • Have had any sort of blood clot (thrombosis) in the last 3 months
  • Have serious problems with your digestive system
  • Have had treatment as part of another clinical trial in the last 4 weeks
  • Are pregnant or breastfeeding
  • Have had any other cancer apart from non melanoma skin cancer or prostate cancer that had not spread and that was successfully treated at least 5 years ago

Trial design

This study will recruit 1,134 patients from the UK and Europe.

This is a randomised trial. The people taking part are put into 1 of 2 treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.

  • People in group 1 have surgery to remove the cancerous kidney as well as sunitinib
  • People in group 2 have sunitinib alone

If you are in group 1, you have your surgery soon after joining the trial Open a glossary item. When you have recovered from the operation, you start sunitinib.

If you are in group 2 you start sunitinib soon after joining the trial.

People in both groups take sunitinib tablets once a day for 4 weeks, followed by 2 weeks with no tablets. This 6 week period is called a treatment cycle. You can carry on taking sunitinib for as long as it helps you.

If you have not already had a biopsy Open a glossary item to confirm that you have clear cell cancer, you will need to have one at the beginning of the trial.

If you have a nephrectomy, the trial team will ask your permission to take a sample of tissue during surgery. This sample will be stored safely and may be looked at in the future by the trial team.

Hospital visits

Before you start the trial you will see the trial doctors and have some tests. These will include

If you are in group 1, you will stay in hospital for your surgery. The length of time you stay in hospital depends on how quickly you recover.

When you start sunitinib you will have the following tests.

  • Physical examination
  • Blood test

You have these every 6 weeks while you are taking sunitinib. You have them again 4 weeks after you stop taking it.

You will have a heart trace (ECG) and a CT or MRI scan every 12 weeks during treatment, and again 4 weeks after you stop taking sunitinib.

Once you have stopped taking the sunitinib, the study team will contact you every 3 months to find out how you are. They will either phone you or see you at the hospital.

Side effects

There can be possible problems after any surgery. These problems can include, pain, infection and slow wound healing. But surgery for kidney cancer can include the following complications

  • Blood clots (DVT)
  • Bleeding

Common side effects of sunitinib include

There is more information about sunitinib on CancerHelp UK.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Mr Michael Aitchison

Supported by

Cancer Research UK
NHS Greater Glasgow and Clyde
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 6174

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page